Oral formulations Oral tirzepatide is in advanced clinical trials
If you found this interesting PLEASE share it

(7)Fmoc-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-WangResin (7) Preparation of Fmoc-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-WangResin (6)Fmoc-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-WangResin(20DMF)5203DMF3DMF2Fmoc-Ala-OH0.7gDIEA0.4mlTBTU0.56gHOBT0.2gDMF 10ml1.53DMF3DMF2Fmoc-Ala-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-WangResin In the Fmoc-Asp(otBu)-Asp(otBu)-Ala-Gly-Leu-Val-WangResin in step (6), add a decapping reagent (20% piperidine in DMF solution), react at room temperature for 5 minutes, and drain, Re-add the capping agent and react at room temperature for 20 minutes, wash with isopropanol for 3 times, DMF for 3 times, re-distilled DMF for 2 times, drain, add Fmoc-Ala-OH0.7g, DIEA0.4ml, TBTU0.56g , HOBT0.2g, DMF 10ml normal temperature reaction 1.5 hours, drained with a vacuum pump, washed 3 times with isopropanol, washed 3 times with DMF, washed 2 times with DMF evaporated, and dried to obtain Fmoc-Ala-Asp(otBu )-Asp(otBu)-Ala-Gly-Leu-Val-WangResin

Band density was quantified and used to determine the level of HGF dimerization in each group
Tirzepatides boxed warning and labeled warnings exist because it completed the review that produces such labeling